Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Reports: Watson Pharma Close To Buying Actavis In A $7 Bln Deal

RELATED NEWS
Trade ACT now with 

Generic drugmaker Watson Pharmaceuticals, Inc. Co. (WPI: Quote) is reportedly close to acquiring privately-held European peer Actavis for about $7 billion. The news sent Watson's shares soaring, which closed higher by nearly 9 percent.

The Swiss firm was taken private in 2007 and Icelandic business tycoon Bjorgolfur Thor Bjorgolfsson has a 78 percent stake in the company.

Parsippany, New Jersey-based Watson's offerings include generic version of cholesterol drug Lipitor and Concerta, intended for attention deficit hyperactivity disorder. The company last month reported a surge in profit for the fourth quarter mainly on strong sales of these two drugs. Actavis also has a business nearly as big as that of Watson and has a formidable presence in central and eastern Europe. It has around 830 products on the market and about 350 products under development and pending registration. The U.S. company may pay 5.0 billion euros to 5.5 billion euros for the Swiss firm.

Among its previous acquisitions, Watson purchased Andrx Corp in 2006 for $1.9 billion and bought Arrow Group for $1.75 billion in 2009. The company last year acquired Specifar Pharmaceuticals of Greece for $562 million.

WPI climbed $5.16 or 8.82 percent on Wednesday to close the session at $63.69 on a volume of 10.86 million shares.

Register
To receive FREE breaking news email alerts for Actavis Plc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Home improvement and building products company Masco Corp. said Monday after the markets closed that its second quarter profit jumped 78% from last year, as revenue increased and margins improved amid strong performance of its Plumbing Products, Installation and Other Services and Decorative Architectural Products segments. American Financial Group Inc. (AFG) Monday reported second-quarter net earnings of $106 million or $1.15 per share, compared to $110 million or $1.20 per share last year. Core net operating earnings were $99 million or $1.07 per share, compared to $87 million or $0.96 per share last year. Total... Stocks showed a significant recovery over the course of the trading day on Monday after coming under pressure in early trading. The markets eventually ended the session roughly flat following the mixed performance that was seen last week.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.